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ABSTRACT 
Assessing medical devices (MDs) raises challenges which require us to reflect on 
whether current methods are adequate. Major features of devices are: (i) device-
operator interaction can generate learning curve effects; (ii) incremental nature of 
innovation needs to be addressed by careful identification of the alternatives for 
comparative and incremental cost-effectiveness analysis) (iii) broader organizational 
impact in terms of training and infrastructure, coupled with dynamic pricing, requires 
a more flexible approach to costing.  
 The objective of the MedtecHTA project was to investigate improvements in HTA 
methods to allow for more comprehensive evaluation of MDs. It consisted of several 
work packages concerning i) the available evidence on the currently adopted 
approaches for regulation and HTA of medical devices; ii) the geographical variation 
in access to MDs; iii) the development of methodological frameworks for conducting 
comparative effectiveness research and economic evaluation of MDs; iv) the 
organizational impact of MDs.  
This introductory paper summarises the main results of the project and draws out the 
main overarching themes. This supplement represents a comprehensive report of all 
the main findings of the MedtecHTA project and it is intended to be the main source 
for researchers and policy makers wanting information on the project. 
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1. Background to the MedtecHTA project 
Health technology assessment (HTA) has become increasingly important in health 
care decision-making in Europe. Although in principle HTA can be applied to all 
health technologies, its major use in a decision-making context has been in the pricing 
and reimbursement of pharmaceuticals. However, there are over 200,000 medical 
devices on the European market (Fraser et al, 2011). These represent a very 
heterogeneous family of technologies that needs to be better classified for the purpose 
of HTA. “Medical device”, according to the EU Directive (2007) 2007/47/EC 
amending Council Directive 93/42/EEC2007/47/EC, is defined as “any instrument, 
apparatus, appliance, software, material or other article, whether used alone or in 
combination.… to be used for human beings for the purpose of diagnosis, prevention, 
treatment, monitoring or alleviation of disease”.  
While some devices require very simplified assessment, others need to be assessed 
through a full evaluation of safety, efficacy, effectiveness and economic impact. A 
thorough HTA would require consideration of final outcomes in terms of life 
expectancy and health-related quality of life, going far beyond the assessment that 
devices currently undergo to obtain a CE (European Conformity) mark, to enable 
them to be marketed in the European Union. This is particularly true for implantable 
devices used in cardiology (Boriani et al., 2009; Boriani, Maniadakis, Auricchio, & 
Vardas, 2010; R. Tarricone & Drummond, 2011), which represent the main focus of 
the MedtecHTA project.  
The current EU legal framework already requires for all devices, especially for class 
III devices, to have safety and performance testing for decision on CE mark.The 
current EU legal framework already requires all high-risk devices (class III) to have 
safety and performance testing for decisions on market authorization. Essentially, 
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manufacturers must accomplish a conformity assessment and undergo an inspection 
and certification procedure by one of the Notified Bodies within the EU. In addition, 
there is stringent post-marketing surveillance, requiring manufacturers of devices to 
implement a post market clinical follow up plan and a medical device vigilance 
system “medical device vigilance system” to monitor their products once they are on 
the market (Cohen & Billingsley, 2011). Conversely, in the United States, a much 
greater importance is given to pre-market approval (PMA), requiring clinical testing 
to inform the market about safety and effectiveness. Nevertheless a much lighter ex-
post conformity assessment is in place. It must be noted however that the EU 
Directives for the regulation of medical devices have been the object of relevant 
amendments in recent years and, although the final document is not available yet, the 
orientation is for more stringent clinical evidential requirements in the pre-market 
phase (European Commission, DG Growth, 2016). 
Nevertheless, medical devices have traditionally been less regulated than 
pharmaceuticals and the amount of evidence collected for licensing medical devices is 
generally lower (Fattore, Maniadakis, Mantovani, & Boriani, 2011; Schreyögg, 
Bäumler, & Busse, 2009; Taylor & Iglesias, 2009). The EU directive in 2007 made 
some significant changes in this respect by recognizing that it is necessary to enhance 
the provisions on clinical evaluation, including clarification that clinical data are 
generally required for all devices (2007/47/EC). Consequently, medical devices 
placed on the EU market or put into service after March 21st 2010 must be in 
conformity with these new requirements. However, in contrast to the requirements for 
pharmaceuticals, due to peculiarity of medical devices, the studies can be small 
clinical trials or even non randomized clinical investigation, and long term efficacy 
data are not generally required in the premarketing phase, although a post market 
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clinical follow up is requiredHowever, in contrast to the requirements for 
pharmaceuticals, the studies can be small clinical trials or even nonrandomized 
clinical investigations, and long-term efficacy data are not required, thus reducing the 
knowledge base for subsequent HTA activities.  
A full HTA, such as that applied to pharmaceuticals in many EU member states, 
would require a thorough examination of the clinical and cost-effectiveness of 
devices. However, medical devices differ from other health technologies in a number 
of respects: i) they often change rapidly; ii) clinical outcomes often depend on the 
training, competence and experience of the end-user (Ramsay et al., 2001); iii) pricing 
is typically more dynamic than that of pharmaceuticals; iv) costs often comprise both 
procurement costs (including the associated infrastructure) and running costs 
(including maintenance and consumables). 
It has been claimed that these special characteristics of devices raise additional 
challenges which require the HTA community to reflect on whether the current 
methods are adequate (Drummond, Griffin, & Tarricone, 2009). Three major  features 
of devices deserve special attention: (i) the device-operator interaction can generate 
learning curve effects and thus risk biases in estimating the size of the benefits; (ii) 
the incremental nature of innovation (e.g., longer battery life, improvement of the 
software systems, miniaturisation)  needs to be addressed by careful identification of 
the alternatives for comparative and incremental cost-effectiveness analysis (Fattore 
et al., 2011; Sorenson, Tarricone, Siebert, & Drummond, 2011; R. Tarricone & 
Drummond, 2011; Taylor & Iglesias, 2009) (iii)  the broader organizational impact in 
terms of training and infrastructure, coupled with dynamic pricing, requires a more 
flexible approach to costing. Whether these  differences between  medical devices and 
pharmaceuticals require a different framework for HTA needs to be investigated.  
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1. The MedtecHTA project 
The objective of MedtecHTA project was to investigate improvements in HTA 
methods to allow for more comprehensive economic evaluation of medical devices. 
The project consisted of seven work packages (WPs), organized in three parts. (see 
Table 1.)  
- TABLE 1 HERE ABOUT - 
 
2.1 Cross country analysis of regulation and HTA of medical devices 
Part 1 of the project was essentially preparatory and included the necessary 
groundwork for the subsequent research activities. WP 1 considered the available 
evidence on the currently adopted approaches for the HTA of medical devices and on 
international regulatory guidance on the licensing of medical devices. Tarricone et al 
(2014) reviewed regulatory practices in the EU, US and 5 other countries and 
concluded that a number of actions are required to make the clinical evidence 
gathered through the regulatory process more relevant to HTA. These include the 
development of international standards on the types of clinical evidence required for 
the market approval of medical devices and agreement on the balance of clinical data 
collection pre- and post-launch.  The latter is important because of the possibility that, 
owing to the learning curve and the organizational impact of devices, data from pre-
launch clinical trials may not be ideal for assessing effectiveness and cost-
effectiveness. 
Ciani et al (2015) reported the results of a cross-country analysis of HTA guidelines 
and available HTA reports on medical devices in assigned countries using a 
standardized template for comparison. In order to analyse the state of the art in the 
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application of guidelines reviewed, a sample of HTA reports was selected from the 
University of York Centre for Reviews of Dissemination HTA database and 
systematically reviewed at three levels (i) assessment of the nature of evidence 
included in the reports (ii) HTA methods applied by reports considering medical 
devices, and (iii) assessment of approaches and methods used to address uncertainty. 
They found that although 75% of the agencies surveyed had adopted HTA-specific 
approaches for medical devices, these were largely organizational or procedural in 
nature. Only one agency had adopted methodological guidelines specific to medical 
devices. 
In the second paper in this supplement, Ciani et al (2016) focus on the second phase 
of their research, in which they analysed a sample of HTA reports in the field of 
cardiovascular disease in order to assess whether there are any key differences in how 
methods are applied. They found that here were several differences, in the types of 
clinical studies forming the basis for the HTAs, how the health problem and use of the 
technology was considered, the description and technical characteristics of the 
technology and the consideration of the organizational aspects of the use of the 
technology. Most of these differences arose due to the relative ‘complexities’ in the 
use of devices, in terms of the number of interacting components. These include the 
number and difficulty of the actions required by those delivering or receiving the 
intervention, the number of groups and organizational levels targeted by the 
intervention, the number and variability of the outcomes and the degree of flexibility 
or tailoring of the intervention. 
 
2.2 Geographical variation in the use of medical devices in the EU 
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Work Package 2 considered the geographical variation in the use of medical devices 
in EU countries by estimating the rate of adoption of selected medical technologies in 
the field of electrophysiology. This subspecialty of cardiology widely uses 
implantable medical devices whose efficacy has been demonstrated by a number of 
randomized clinical trials. In one respect these devices resemble pharmaceuticals as 
they have a curative and/or a secondary prevention function and can might be tested 
in clinical trials similar to those conducted on drugs. On the other hand, they differ 
from pharmaceuticals because they are subjected to incremental changes (e.g. 
dimensions and software), learning curve effects due to device-operator interactions 
and price dynamics which make trial designs similar to pharmaceuticals not always 
suitable for medical devices. These overall characteristics make the area of 
electrophysiology an interesting case to study.  
Results obtained in this field also have a higher degree of transferability to other class 
III medical devices. Through the analysis of national/local guidelines and data from 
registries and administrative databases, rates of utilization were mapped to provide 
evidence of different degrees of access within member states, and whether this 
adoption is in line with the existing evidence on clinical and cost effectiveness. 
Valzania et al (2015) reported a systematic review of the literature on implant rates 
for cardiac implantable electrical devices (CIEDs) in Europe. They found that there 
had been a recent rise in implant rates, with large geographic differences. For 
example, the ratio between the regions with the highest and lowest implant rates 
within the same country ranged from 1.3 and 3.4 for cardiac pacemakers, whereas the 
ratio between the countries with the highest and lowest implant rates ranged from 2.3 
and 87.5. The determinants of these differences (namely epidemiological, cultural, 
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and socio-economic factors) were only partly explored and differences in study 
methodology could be one reason for the reported differences.  
Therefore, in a subsequent phase of the research, reported in the third paper in this 
supplement, Torbica et al (2016a) undertook a new study of implant rates, the first to 
use the national hospital discharge datasets available in 5 EU countries. They provide 
evidence on differences in use of medical devices within and between member states, 
investigate the determinants of differences in access to CIEDs, and assess the 
potential and limitations of administrative databases for the analysis of utilization 
rates of medical devices in electrophysiology. 
 It is the first international paper to explore simultaneously differences both between 
countries and within the regions of those countries. Results show , that higher levels 
of tertiary education among the labor force and % of aged population are positively 
associated with implant rates of CIED. Regional per capita GDP and number of 
implanting centers appear to have no significant effect. Institutional factors, captured 
by fixed country effect, are shown to be important for the diffusion of CIED.  
 
 
Regional per capita GDP appeared to have a small, but significant, effect on use of 
CIEDs. In addition, the % of residents having tertiary education, the age of the 
population and life expectancy were associated with higher implant rates. Increased 
competition (expressed in terms of the implant rates in each region), fostered the use 
of technologies. However, even after controlling for clinical, epidemiological and 
(crude) economic indicators, significant variation in implant rates still exist. They 
argue that there should be closer examination of the role of organizational factors and 
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clinical preferences in the adoption of devices. These issues are explored further in 
WP6 of the MedtecHTA project (discussed below). 
 
2.3 Methods for assessing the comparative effectiveness of medical devices 
 
The core part of the project (Part II) sought to develop an improved methodological 
framework for conducting HTA of medical devices by acknowledging the 
complexities which arise from their integration into clinical practice. The research 
conducted in WP3, began by considering the approaches and methodologies used for 
comparative effectiveness research by conducting a systematic review of the 
methodological literature. It was found that, although most of the good research 
practices in the evaluation of all health technologies apply to medical devices, the 
interventions involving the use of medical devices should be considered as complex 
interventions, owing to the importance of user and context independence. Therefore, 
specific randomized controlled trial designs need to be considered, dealing with 
surgeons’ and patients’ preferences, incremental product development and user 
dependence. In addition, high quality disease- or device-based registries are needed to 
assess safety and long-term effectiveness (Schnell-Inderst et al, 2016a). 
This preliminary research activity provided the basis for the development of improved 
methods for evaluating comparative effectiveness of medical devices including 
recommendations for analytic methods and data collection. The research was an 
important input to the development of guidelines for the evaluation of Therapeutic 
Medical Devices under the auspices of the EUnetHTA Joint Action 2 (EUnetHTA, 
2015). 
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The framework and new methodological approaches were then tested on medical 
devices at different stages of development and diffusion within the health care system. 
First, the use of a method of evidence synthesis that allows for the meta-analysis of 
RCT and observational data, using bias adjustment based on a formal elicitation 
exercise involving experts, was explored in the case of total hip replacement. This is 
reported in the fourth paper in this supplement (Schnell-Inderst et al, 2016b).  
 
2.4 Methods for the economic evaluation of medical devices 
Work Package 4 focused on exploring different methods for economic evaluation of 
medical devices currently adopted in EU countries in order to make suggestions about 
the development of new methods and offer guidance on future directions in the use of 
economic evaluation for medical devices. The first part of the research considered 
how differences in culture and values in EU countries lead to differences in the 
methodology and use of economic evaluation for policy decisions such as coverage 
and reimbursement without distinguishing between health technologies (e.g. 
pharmaceuticals and medical devices). For example, in northern Europe, economic 
evaluation is widely used in decisions about the reimbursement of new health 
technologies and cost-utility analysis (with the quality-adjusted life-year as the 
primary measure of benefit) is the predominant approach. In UK, the National 
institute for Health and Clinical Excellence (2011) has differentiated between health 
technologies and has developed the Medical Technologies Evaluation Programme to 
specifically assess medical devices and diagnostics. In contrast, in central and 
southern Europe, there is more resistance to the use of economic evaluation in 
decision making and, where it is used, benefits are more often assessed in terms of 
clinical added value. In these countries however no distinction is made between health 
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technologies and policy decisions on coverage and reimbursement of medical devices 
are generally not subject to any type of economic analysis.  This part of the research 
provided useful insights into the potential for increasing the use of economic 
evaluation in various EU member states (Torbica et al, 2016b). 
The second part of the research, reported in the fifth paper of this supplement 
(Tarricone et al, 2016a) used two case studies of implantable cardiac devices in order 
to demonstrate current, and possible future approaches to the use of economic 
evaluation. The case studies, implantable converter cardioverter defibrillators (ICDs) 
and transcatheter aortic valve implantation (TAVI) were chosen in order to explore a 
wide range of device characteristics, including the significance of irreversible 
decisions and the complexity associated with evolving technologies. Most of the 
published economic evaluations and HTA reports located in the literature review did 
not take account of the special features of medical devices (i.e. learning curves, 
incremental innovation, dynamic pricing and organizational aspects) in the base case 
analysis, but were sometimes considered in sensitivity analyses. Overall, the 
conclusion was that the existing economic evaluations did not pay enough attention to 
the specific characteristics of devices explored in the MedtecHTA project. 
Finally, building on the findings of both WP3 and WP4, the impact of the learning 
curve on effectiveness and cost was estimated for endovascular aneurysm repair 
(EVAR) and fenestrated EVAR (fEVAR). This research is reported in the sixth paper 
in this supplement (Varabyova et al, 2016). It was found that, in the case of EVAR 
there was a moderate, but significant effect of learning on both in-hospital mortality 
and hospital length of stay. The same impact was not found for fEVAR, one reason 
for which could be its similarity to EVAR, meaning that much of the learning in 
EVAR was transferable to the new procedure 
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2.5 Uncertainty in the economic evaluation of medical devices 
Work Package 5 focused on characterizing uncertainty in the economic evaluation of 
medical devices and determining future research needs. This research, reported in the 
seventh paper in this supplement (Rothery et al, 2016), sets out a number of 
conceptual issues when dealing with uncertainty and the value of research in the 
context of some of the specific characteristics of devices such as learning curve 
effects, incremental device innovation and dynamic pricing. It uses value of 
information analysis to explore the optimal timing of reimbursement decisions and the 
suitability of conditional coverage decisions, such as ‘only in research’ and ‘approval 
with research’.  
Such conditional reimbursement policies are now becoming popular in a number of 
countries, given the growing recognition that, for medical devices, there will always 
be considerable evidence gaps, particularly in evidence on effectiveness. As in the 
other WPs, a case study is chosen to illustrate the use of methods at different stages of 
device development and diffusion. The example chosen is enhanced external 
counterpulsation (EECP), a device used to provide symptomatic relief from chronic 
refractory angina, where the existence of substantial irrecoverable costs and price 
changes have a substantial impact on coverage decisions.  
 
2.6 Organizational impact of medical devices 
The final methodological issue investigated in the MedtecHTA project was the 
organizational impact of medical devices. In this part of the project the aim was to 
propose a methodology that will allow for incorporating organizational issues in a 
broader HTA framework. A systematic review of the literature was conducted, which 
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was used to develop a large, (54 item) survey of cardiologists, conducted in 
collaboration with the European Society of Cardiology. The objective was to explore 
the role of physicians’ motivation and organizational factors in the adoption and 
diffusion of medical devices. The survey focused on 7 different catheter-based or 
implantable cardiovascular devices. Multivariate hierarchical modeling was used to 
determine the associations between the various motivational and organizational 
factors and device diffusion and use. This research is reported in the eighth paper in 
this supplement (Hatz et al, 2016).  
 
2. Dissemination of project findings 
In the final phase of the project (Part III), the findings and results from the previous 
phases were collated into a final report (WP7), which provides recommendations for 
decision-makers, in formulating health policy, within the medical devices industry, as 
well as in the management of health care organizations. In addition, recommendations 
on developments in methodology were made for the scientific community. These 
recommendations are summarized in the final paper in this supplement (Tarricone et 
al, 2016b). These are divided into; recommendations for policy, recommendations for 
methods and recommendations for further research.  
Taken together, the papers in this supplement represent a comprehensive report of all 
the main findings of the MedtecHTA project and give references to other published 
outputs for the project. It is intended to be the main source for researchers and policy 
makers requiring information on the project. 
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Table 1  Overview of project work plan 
Parts of the overall project Work packages included 
I: Cross-country analysis of HTA 
practices  
and utilization of medical devices  
 
WP 1 Cross-country Analysis of HTA 
WP 2 Geographic variation in access to 
medical devices 
II: Methodological issues in HTA of 
medical devices 
WP 3 Comparative effectiveness of 
medical devices 
WP 4 Economic evaluation of medical 
devices: overview of different approaches 
WP 5 Uncertainty and Value of 
Information for medical devices 
WP 6 Organizational impact of medical 
devices 
III: Conclusions, synthesis and 
recommendations  
 
WP 7 Recommendations on HTA 
methods for medical devices   
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Challenges in the Assessment of Medical Devices: the MedtecHTA project 
 
Keywords: MedtecHTA, medical devices, Health Technology Assessment, economic 
evaluation, methods 
Page 18 of 34
http://mc.manuscriptcentral.com/hec
Health Economics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
2 
 
ABSTRACT 
Assessing medical devices (MDs) raises challenges which require us to reflect on 
whether current methods are adequate. Major features of devices are: (i) device-
operator interaction can generate learning curve effects; (ii) incremental nature of 
innovation needs to be addressed by careful identification of the alternatives for 
comparative and incremental cost-effectiveness analysis) (iii) broader organizational 
impact in terms of training and infrastructure, coupled with dynamic pricing, requires 
a more flexible approach to costing.  
 The objective of the MedtecHTA project was to investigate improvements in HTA 
methods to allow for more comprehensive evaluation of MDs. It consisted of several 
work packages concerning i) the available evidence on the currently adopted 
approaches for regulation and HTA of medical devices; ii) the geographical variation 
in access to MDs; iii) the development of methodological frameworks for conducting 
comparative effectiveness research and economic evaluation of MDs; iv) the 
organizational impact of MDs.  
This introductory paper summarises the main results of the project and draws out the 
main overarching themes. This supplement represents a comprehensive report of all 
the main findings of the MedtecHTA project and it is intended to be the main source 
for researchers and policy makers wanting information on the project. 
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1. Background to the MedtecHTA project 
Health technology assessment (HTA) has become increasingly important in health 
care decision-making in Europe. Although in principle HTA can be applied to all 
health technologies, its major use in a decision-making context has been in the pricing 
and reimbursement of pharmaceuticals. However, there are over 200,000 medical 
devices on the European market (Fraser et al, 2011). These represent a very 
heterogeneous family of technologies that needs to be better classified for the purpose 
of HTA. “Medical device”, according to the EU Directive (2007) 2007/47/EC 
amending Council Directive 93/42/EEC, is defined as “any instrument, apparatus, 
appliance, software, material or other article, whether used alone or in combination.… 
to be used for human beings for the purpose of diagnosis, prevention, treatment, 
monitoring or alleviation of disease”.  
While some devices require very simplified assessment, others need to be assessed 
through a full evaluation of safety, efficacy, effectiveness and economic impact. A 
thorough HTA would require consideration of final outcomes in terms of life 
expectancy and health-related quality of life, going far beyond the assessment that 
devices currently undergo to obtain a CE (European Conformity) mark, to enable 
them to be marketed in the European Union. This is particularly true for implantable 
devices used in cardiology (Boriani et al., 2009; Boriani, Maniadakis, Auricchio, & 
Vardas, 2010; R. Tarricone & Drummond, 2011), which represent the main focus of 
the MedtecHTA project.  
The current EU legal framework already requires for all devices, especially for class 
III devices, to have safety and performance testing for decision on CE mark.. 
Essentially, manufacturers must accomplish a conformity assessment and undergo an 
inspection and certification procedure by one of the Notified Bodies within the EU. In 
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addition, there is stringent post-marketing surveillance, requiring manufacturers of 
devices to implement a post market clinical follow up plan and a medical device 
vigilance system to monitor their products once they are on the market (Cohen & 
Billingsley, 2011). Conversely, in the United States, a much greater importance is 
given to pre-market approval (PMA), requiring clinical testing to inform the market 
about safety and effectiveness. Nevertheless a much lighter ex-post conformity 
assessment is in place. It must be noted however that the EU Directives for the 
regulation of medical devices have been the object of relevant amendments in recent 
years and, although the final document is not available yet, the orientation is for more 
stringent clinical evidential requirements in the pre-market phase (European 
Commission, DG Growth, 2016). 
Nevertheless, medical devices have traditionally been less regulated than 
pharmaceuticals and the amount of evidence collected for licensing medical devices is 
generally lower (Fattore, Maniadakis, Mantovani, & Boriani, 2011; Schreyögg, 
Bäumler, & Busse, 2009; Taylor & Iglesias, 2009). The EU directive in 2007 made 
some significant changes in this respect by recognizing that it is necessary to enhance 
the provisions on clinical evaluation, including clarification that clinical data are 
generally required for all devices (2007/47/EC). Consequently, medical devices 
placed on the EU market or put into service after March 21
st
 2010 must be in 
conformity with these new requirements. However, in contrast to the requirements for 
pharmaceuticals, due to peculiarity of medical devices, the studies can be small 
clinical trials or even non randomized clinical investigation, and long term efficacy 
data are not generally required in the premarketing phase, although a post market 
clinical follow up is required, thus reducing the knowledge base for subsequent HTA 
activities.  
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A full HTA, such as that applied to pharmaceuticals in many EU member states, 
would require a thorough examination of the clinical and cost-effectiveness of 
devices. However, medical devices differ from other health technologies in a number 
of respects: i) they often change rapidly; ii) clinical outcomes often depend on the 
training, competence and experience of the end-user (Ramsay et al., 2001); iii) pricing 
is typically more dynamic than that of pharmaceuticals; iv) costs often comprise both 
procurement costs (including the associated infrastructure) and running costs 
(including maintenance and consumables). 
It has been claimed that these special characteristics of devices raise additional 
challenges which require the HTA community to reflect on whether the current 
methods are adequate (Drummond, Griffin, & Tarricone, 2009). Three major  features 
of devices deserve special attention: (i) the device-operator interaction can generate 
learning curve effects and thus risk biases in estimating the size of the benefits; (ii) 
the incremental nature of innovation (e.g., longer battery life, improvement of the 
software systems, miniaturisation)  needs to be addressed by careful identification of 
the alternatives for comparative and incremental cost-effectiveness analysis (Fattore 
et al., 2011; Sorenson, Tarricone, Siebert, & Drummond, 2011; R. Tarricone & 
Drummond, 2011; Taylor & Iglesias, 2009) (iii)  the broader organizational impact in 
terms of training and infrastructure, coupled with dynamic pricing, requires a more 
flexible approach to costing. Whether these  differences between  medical devices and 
pharmaceuticals require a different framework for HTA needs to be investigated.  
 
1. The MedtecHTA project 
The objective of MedtecHTA project was to investigate improvements in HTA 
methods to allow for more comprehensive economic evaluation of medical devices. 
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The project consisted of seven work packages (WPs), organized in three parts. (see 
Table 1.)  
- TABLE 1 HERE ABOUT - 
 
2.1 Cross country analysis of regulation and HTA of medical devices 
Part 1 of the project was essentially preparatory and included the necessary 
groundwork for the subsequent research activities. WP 1 considered the available 
evidence on the currently adopted approaches for the HTA of medical devices and on 
international regulatory guidance on the licensing of medical devices. Tarricone et al 
(2014) reviewed regulatory practices in the EU, US and 5 other countries and 
concluded that a number of actions are required to make the clinical evidence 
gathered through the regulatory process more relevant to HTA. These include the 
development of international standards on the types of clinical evidence required for 
the market approval of medical devices and agreement on the balance of clinical data 
collection pre- and post-launch.  The latter is important because of the possibility that, 
owing to the learning curve and the organizational impact of devices, data from pre-
launch clinical trials may not be ideal for assessing effectiveness and cost-
effectiveness. 
Ciani et al (2015) reported the results of a cross-country analysis of HTA guidelines 
and available HTA reports on medical devices in assigned countries using a 
standardized template for comparison. In order to analyse the state of the art in the 
application of guidelines reviewed, a sample of HTA reports was selected from the 
University of York Centre for Reviews of Dissemination HTA database and 
systematically reviewed at three levels (i) assessment of the nature of evidence 
included in the reports (ii) HTA methods applied by reports considering medical 
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devices, and (iii) assessment of approaches and methods used to address uncertainty. 
They found that although 75% of the agencies surveyed had adopted HTA-specific 
approaches for medical devices, these were largely organizational or procedural in 
nature. Only one agency had adopted methodological guidelines specific to medical 
devices. 
In the second paper in this supplement, Ciani et al (2016) focus on the second phase 
of their research, in which they analysed a sample of HTA reports in the field of 
cardiovascular disease in order to assess whether there are any key differences in how 
methods are applied. They found that here were several differences, in the types of 
clinical studies forming the basis for the HTAs, how the health problem and use of the 
technology was considered, the description and technical characteristics of the 
technology and the consideration of the organizational aspects of the use of the 
technology. Most of these differences arose due to the relative ‘complexities’ in the 
use of devices, in terms of the number of interacting components. These include the 
number and difficulty of the actions required by those delivering or receiving the 
intervention, the number of groups and organizational levels targeted by the 
intervention, the number and variability of the outcomes and the degree of flexibility 
or tailoring of the intervention. 
 
2.2 Geographical variation in the use of medical devices in the EU 
Work Package 2 considered the geographical variation in the use of medical devices 
in EU countries by estimating the rate of adoption of selected medical technologies in 
the field of electrophysiology. This subspecialty of cardiology widely uses 
implantable medical devices whose efficacy has been demonstrated by a number of 
randomized clinical trials. In one respect these devices resemble pharmaceuticals as 
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they have a curative and/or a secondary prevention function and might be tested in 
clinical trials similar to those conducted on drugs. On the other hand, they differ from 
pharmaceuticals because they are subjected to incremental changes (e.g. dimensions 
and software), learning curve effects due to device-operator interactions and price 
dynamics which make trial designs similar to pharmaceuticals not always suitable for 
medical devices. These overall characteristics make the area of electrophysiology an 
interesting case to study.  
Results obtained in this field also have a higher degree of transferability to other class 
III medical devices. Through the analysis of national/local guidelines and data from 
registries and administrative databases, rates of utilization were mapped to provide 
evidence of different degrees of access within member states, and whether this 
adoption is in line with the existing evidence on clinical and cost effectiveness. 
Valzania et al (2015) reported a systematic review of the literature on implant rates 
for cardiac implantable electrical devices (CIEDs) in Europe. They found that there 
had been a recent rise in implant rates, with large geographic differences. For 
example, the ratio between the regions with the highest and lowest implant rates 
within the same country ranged from 1.3 and 3.4 for cardiac pacemakers, whereas the 
ratio between the countries with the highest and lowest implant rates ranged from 2.3 
and 87.5. The determinants of these differences (namely epidemiological, cultural, 
and socio-economic factors) were only partly explored and differences in study 
methodology could be one reason for the reported differences.  
Therefore, in a subsequent phase of the research, reported in the third paper in this 
supplement, Torbica et al (2016a) undertook a new study of implant rates, the first to 
use the national hospital discharge datasets available in 5 EU countries. They provide 
evidence on differences in use of medical devices within and between member states, 
Page 25 of 34
http://mc.manuscriptcentral.com/hec
Health Economics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
9 
 
investigate the determinants of differences in access to CIEDs, and assess the 
potential and limitations of administrative databases for the analysis of utilization 
rates of medical devices in electrophysiology. 
 It is the first international paper to explore simultaneously differences both between 
countries and within the regions of those countries. Results show that higher levels of 
tertiary education among the labor force and % of aged population are positively 
associated with implant rates of CIED. Regional per capita GDP and number of 
implanting centers appear to have no significant effect. Institutional factors, captured 
by fixed country effect, are shown to be important for the diffusion of CIED.  
 
 
However, even after controlling for clinical, epidemiological and (crude) economic 
indicators, significant variation in implant rates still exist. They argue that there 
should be closer examination of the role of organizational factors and clinical 
preferences in the adoption of devices. These issues are explored further in WP6 of 
the MedtecHTA project (discussed below). 
 
2.3 Methods for assessing the comparative effectiveness of medical devices 
 
The core part of the project (Part II) sought to develop an improved methodological 
framework for conducting HTA of medical devices by acknowledging the 
complexities which arise from their integration into clinical practice. The research 
conducted in WP3, began by considering the approaches and methodologies used for 
comparative effectiveness research by conducting a systematic review of the 
methodological literature. It was found that, although most of the good research 
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practices in the evaluation of all health technologies apply to medical devices, the 
interventions involving the use of medical devices should be considered as complex 
interventions, owing to the importance of user and context independence. Therefore, 
specific randomized controlled trial designs need to be considered, dealing with 
surgeons’ and patients’ preferences, incremental product development and user 
dependence. In addition, high quality disease- or device-based registries are needed to 
assess safety and long-term effectiveness (Schnell-Inderst et al, 2016a). 
This preliminary research activity provided the basis for the development of improved 
methods for evaluating comparative effectiveness of medical devices including 
recommendations for analytic methods and data collection. The research was an 
important input to the development of guidelines for the evaluation of Therapeutic 
Medical Devices under the auspices of the EUnetHTA Joint Action 2 (EUnetHTA, 
2015). 
The framework and new methodological approaches were then tested on medical 
devices at different stages of development and diffusion within the health care system. 
First, the use of a method of evidence synthesis that allows for the meta-analysis of 
RCT and observational data, using bias adjustment based on a formal elicitation 
exercise involving experts, was explored in the case of total hip replacement. This is 
reported in the fourth paper in this supplement (Schnell-Inderst et al, 2016b).  
 
2.4 Methods for the economic evaluation of medical devices 
Work Package 4 focused on exploring different methods for economic evaluation of 
medical devices currently adopted in EU countries in order to make suggestions about 
the development of new methods and offer guidance on future directions in the use of 
economic evaluation for medical devices. The first part of the research considered 
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how differences in culture and values in EU countries lead to differences in the 
methodology and use of economic evaluation for policy decisions such as coverage 
and reimbursement without distinguishing between health technologies (e.g. 
pharmaceuticals and medical devices). For example, in northern Europe, economic 
evaluation is widely used in decisions about the reimbursement of new health 
technologies and cost-utility analysis (with the quality-adjusted life-year as the 
primary measure of benefit) is the predominant approach. In UK, the National 
institute for Health and Clinical Excellence (2011) has differentiated between health 
technologies and has developed the Medical Technologies Evaluation Programme to 
specifically assess medical devices and diagnostics. In contrast, in central and 
southern Europe, there is more resistance to the use of economic evaluation in 
decision making and, where it is used, benefits are more often assessed in terms of 
clinical added value. In these countries however no distinction is made between health 
technologies and policy decisions on coverage and reimbursement of medical devices 
are generally not subject to any type of economic analysis. This part of the research 
provided useful insights into the potential for increasing the use of economic 
evaluation in various EU member states (Torbica et al, 2016b). 
The second part of the research, reported in the fifth paper of this supplement 
(Tarricone et al, 2016a) used two case studies of implantable cardiac devices in order 
to demonstrate current, and possible future approaches to the use of economic 
evaluation. The case studies, implantable cardioverter defibrillators (ICDs) and 
transcatheter aortic valve implantation (TAVI) were chosen in order to explore a wide 
range of device characteristics, including the significance of irreversible decisions and 
the complexity associated with evolving technologies. Most of the published 
economic evaluations and HTA reports located in the literature review did not take 
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account of the special features of medical devices (i.e. learning curves, incremental 
innovation, dynamic pricing and organizational aspects) in the base case analysis, but 
were sometimes considered in sensitivity analyses. Overall, the conclusion was that 
the existing economic evaluations did not pay enough attention to the specific 
characteristics of devices explored in the MedtecHTA project. 
Finally, building on the findings of both WP3 and WP4, the impact of the learning 
curve on effectiveness and cost was estimated for endovascular aneurysm repair 
(EVAR) and fenestrated EVAR (fEVAR). This research is reported in the sixth paper 
in this supplement (Varabyova et al, 2016). It was found that, in the case of EVAR 
there was a moderate, but significant effect of learning on both in-hospital mortality 
and hospital length of stay. The same impact was not found for fEVAR, one reason 
for which could be its similarity to EVAR, meaning that much of the learning in 
EVAR was transferable to the new procedure 
 
2.5 Uncertainty in the economic evaluation of medical devices 
Work Package 5 focused on characterizing uncertainty in the economic evaluation of 
medical devices and determining future research needs. This research, reported in the 
seventh paper in this supplement (Rothery et al, 2016), sets out a number of 
conceptual issues when dealing with uncertainty and the value of research in the 
context of some of the specific characteristics of devices such as learning curve 
effects, incremental device innovation and dynamic pricing. It uses value of 
information analysis to explore the optimal timing of reimbursement decisions and the 
suitability of conditional coverage decisions, such as ‘only in research’ and ‘approval 
with research’.  
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Such conditional reimbursement policies are now becoming popular in a number of 
countries, given the growing recognition that, for medical devices, there will always 
be considerable evidence gaps, particularly in evidence on effectiveness. As in the 
other WPs, a case study is chosen to illustrate the use of methods at different stages of 
device development and diffusion. The example chosen is enhanced external 
counterpulsation (EECP), a device used to provide symptomatic relief from chronic 
refractory angina, where the existence of substantial irrecoverable costs and price 
changes have a substantial impact on coverage decisions.  
 
2.6 Organizational impact of medical devices 
The final methodological issue investigated in the MedtecHTA project was the 
organizational impact of medical devices. In this part of the project the aim was to 
propose a methodology that will allow for incorporating organizational issues in a 
broader HTA framework. A systematic review of the literature was conducted, which 
was used to develop a large (54 item) survey of cardiologists, conducted in 
collaboration with the European Society of Cardiology. The objective was to explore 
the role of physicians’ motivation and organizational factors in the adoption and 
diffusion of medical devices. The survey focused on 7 different catheter-based or 
implantable cardiovascular devices. Multivariate hierarchical modeling was used to 
determine the associations between the various motivational and organizational 
factors and device diffusion and use. This research is reported in the eighth paper in 
this supplement (Hatz et al, 2016).  
 
2. Dissemination of project findings 
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In the final phase of the project (Part III), the findings and results from the previous 
phases were collated into a final report (WP7), which provides recommendations for 
decision-makers, in formulating health policy, within the medical devices industry, as 
well as in the management of health care organizations. In addition, recommendations 
on developments in methodology were made for the scientific community. These 
recommendations are summarized in the final paper in this supplement (Tarricone et 
al, 2016b). These are divided into; recommendations for policy, recommendations for 
methods and recommendations for further research.  
Taken together, the papers in this supplement represent a comprehensive report of all 
the main findings of the MedtecHTA project and give references to other published 
outputs for the project. It is intended to be the main source for researchers and policy 
makers requiring information on the project. 
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Table 1  Overview of project work plan 
Parts of the overall project Work packages included 
I: Cross-country analysis of HTA 
practices  
and utilization of medical devices  
 
WP 1 Cross-country Analysis of HTA 
WP 2 Geographic variation in access to 
medical devices 
II: Methodological issues in HTA of 
medical devices 
WP 3 Comparative effectiveness of 
medical devices 
WP 4 Economic evaluation of medical 
devices: overview of different approaches 
WP 5 Uncertainty and Value of 
Information for medical devices 
WP 6 Organizational impact of medical 
devices 
III: Conclusions, synthesis and 
recommendations  
 
WP 7 Recommendations on HTA 
methods for medical devices   
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